Australia markets close in 4 hours 5 minutes

Soleno Therapeutics, Inc. (SLNO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.9900+0.0190 (+1.96%)
At close: 04:00PM EST
0.9600 -0.03 (-3.03%)
After hours: 04:04PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.9710
Open0.9700
Bid0.9721 x 2200
Ask1.0200 x 1400
Day's range0.9700 - 1.0200
52-week range0.9000 - 9.7200
Volume54,734
Avg. volume71,568
Market cap8.078M
Beta (5Y monthly)0.31
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

    REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and nine months ended September 30, 2022. Third Quarter 2022 and Recent Corporate Highlights Initiated the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Chol

  • GlobeNewswire

    Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

    REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has initiated a randomized withdrawal period of Study C602, an ongoing open-label extension study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS). “Initiation of the randomized withdrawal per

  • GlobeNewswire

    Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

    REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Global Investment Conference, being held September 12-14, 2022, virtually and in-person at the Lotte New York Palace Hotel in New York, NY. The presen